Literature DB >> 27934619

A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms.

Kazushi Ishikawa1, Tomoko Shono-Saito1, Tomoko Yamate1, Yoshitaka Kai1, Takashi Sakai1, Fumiaki Shimizu2, Yasunari Yamada3, Hiromu Mori3, Shinsuke Noso4, Hiroshi Ikegami4, Hiroto Kojima5, Hidenori Tanaka5, Sakuhei Fujiwara1, Yutaka Hatano1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27934619     DOI： 10.1684/ejd.2016.2923

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  12 in total

1.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29

Review 3.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 4.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 5.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

6.  Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab.

Authors:  Nora Chokr; Hafsa Farooq; Elizabeth Guadalupe
Journal:  Case Rep Oncol Med       Date:  2018-01-28

7.  New-onset insulin-dependent diabetes due to nivolumab.

Authors:  Ali A Zaied; Halis K Akturk; Richard W Joseph; Augustine S Lee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-03-28

8.  Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

Authors:  Jeroen M K de Filette; Joeri J Pen; Lore Decoster; Thomas Vissers; Bert Bravenboer; Bart J Van der Auwera; Frans K Gorus; Bart O Roep; Sandrine Aspeslagh; Bart Neyns; Brigitte Velkeniers; Aan V Kharagjitsingh
Journal:  Eur J Endocrinol       Date:  2019-09       Impact factor: 6.664

Review 9.  Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.

Authors:  Maria Stelmachowska-Banaś; Izabella Czajka-Oraniec
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

Review 10.  Endocrine toxicity of cancer immunotherapy: clinical challenges.

Authors:  Bliss Anderson; Daniel L Morganstein
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.